Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 90


Spinal epidural haematoma following rivaroxaban administration after total knee replacement.

Madhisetti KR, Mathew M, George M, Pillai SS.

Indian J Anaesth. 2015 Aug;59(8):519-21. doi: 10.4103/0019-5049.163006. No abstract available.


Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery.

Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y.

J Orthop Surg Res. 2015 May 23;10:78. doi: 10.1186/s13018-015-0223-7.


Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.

Kwong L, Turpie AG.

Curr Orthop Pract. 2015 May;26(3):299-305. Review.


Thromboembolic disease after knee arthroplasty is rare in Southern Iran.

Hossain Shahcheraghi G, Javid M, Arasteh MM.

J Orthop. 2014 Jan 31;12(2):86-91. doi: 10.1016/j.jor.2014.01.003. eCollection 2015 Jun.


Clinical Decision Support-based Quality Measurement (CDS-QM) Framework: Prototype Implementation, Evaluation, and Future Directions.

Kukhareva PV, Kawamoto K, Shields DE, Barfuss DT, Halley AM, Tippetts TJ, Warner PB, Bray BE, Staes CJ.

AMIA Annu Symp Proc. 2014 Nov 14;2014:825-34. eCollection 2014.


Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F.

Thromb J. 2014 Nov 4;12:24. doi: 10.1186/1477-9560-12-24. eCollection 2014. Review.


Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.

Laurent M, Joimel U, Varin R, Cazin L, Gest C, Le-Cam-Duchez V, Jin J, Liu J, Vannier JP, Lu H, Soria J, Li H, Soria C.

Exp Hematol Oncol. 2014 Dec 17;3(1):30. doi: 10.1186/2162-3619-3-30. eCollection 2014.


Pharmacological prevention of venous thromboembolism in orthopaedic surgery.

Prisco D, Cenci C, Silvestri E, Emmi G, Ciucciarelli L.

Clin Cases Miner Bone Metab. 2014 Sep;11(3):192-5. Review.


A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.

Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F.

Clin Pharmacol. 2014 Nov 13;6:179-87. doi: 10.2147/CPAA.S61131. eCollection 2014.


Thromboprophylaxis and orthopaedic surgery: options and current guidelines.

Solayar GN, Shannon FJ.

Malays J Med Sci. 2014 May;21(3):71-7.


Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.

Trujillo T, Dobesh PP.

Drugs. 2014 Sep;74(14):1587-603. doi: 10.1007/s40265-014-0278-5. Review. Erratum in: Drugs. 2014 Oct;74(15):1837.


Evaluating the impact of new anticoagulants in the hospital setting.

Braidy N, Bui K, Bajorek B.

Pharm Pract (Granada). 2011 Jan;9(1):1-10. Epub 2011 Mar 15.


Edoxaban: an update on the new oral direct factor Xa inhibitor.

Bounameaux H, Camm AJ.

Drugs. 2014 Jul;74(11):1209-31. doi: 10.1007/s40265-014-0261-1. Review. Erratum in: Drugs. 2014 Aug;74(12):1455.


Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.

Lessire S, Dincq AS, Douxfils J, Devalet B, Nicolas JB, Spinewine A, Larock AS, Dogné JM, Gourdin M, Mullier F.

Biomed Res Int. 2014;2014:616405. doi: 10.1155/2014/616405. Epub 2014 Jun 16. Erratum in: Biomed Res Int. 2014;2014:347031. multiple author names corrected.


Anticoagulant therapy in pediatrics.

Dabbous MK, Sakr FR, Malaeb DN.

J Basic Clin Pharm. 2014 Mar;5(2):27-33. doi: 10.4103/0976-0105.134947. Review.


Direct oral anticoagulants: integration into clinical practice.

Cowell RP.

Postgrad Med J. 2014 Sep;90(1067):529-39. doi: 10.1136/postgradmedj-2013-132474. Epub 2014 Jul 10. Review.


An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.

Moore KT, Vaidyanathan S, Natarajan J, Ariyawansa J, Haskell L, Turner KC.

J Clin Pharmacol. 2014 Dec;54(12):1407-20. doi: 10.1002/jcph.352. Epub 2014 Jul 3.


Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk